LILLY ZYPREXA SHARE OF NEW ANTIPSYCHOTIC SCRIPTS INCREASES TO 12.9% IN JUNE; EVISTA PRIORITY REVIEW STATUS COULD GIVE LILLY A LATE 1997 APPROVAL
Executive Summary
Lilly's anti-psychotic Zyprexa (olanzapine) has captured almost 13% of new prescriptions through June, the company reported July 23. Zyprexa sales reached $156 mil. for the second quarter, the product's third quarter on the market. The product is tracking to reach $500 mil. in sales during its first 12 months of availability. Its market share at the end of June was 12.9%, up from 6% in January.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth